Release of Research Publication using Tribody Technology onto Cancer Immunotherapy from Chiome Bioscience in collaboration with Ceinge

On March 24, 2022 The publication is reported on a basis of the research using our Tribody technology (Press release, Chiome Bioscience, MAR 24, 2022, View Source [SID1234625712]). Tribody
tecnhology is one of our platform antibody engineering technologies that can generate multi-specific antibody applying for cancer immunotherapy. The research outcomes are published at International Journal of Molecular Sciences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This research is conducted in collaboration with Ceinge Biotecnologie Avanzate ("Ceinge"), a nonprofit consortium research organization in Italy. We constructed novel bi-specific tribodies targeting different molecules involved in immune checkpoints. The tribody exhibited the retained binding activity to each target, increased immuno-modulatory effect to induce lymphocyte activation, and enhanced in vitro cytotoxicity against tumor cells. Tribody format could also reduce the production costs. Also, the molecular size is well suited for both tumor penetration and an acceptable half-life. Tribody could offer useful therapeutic applications, particularly in monotherapy-resistant cancer patients.

Publication

T i t l e ： Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and
Increase Anti-Tumor Efficacy

Authors ： Margherita Passariello, Asami Yoshioka, Kota Takahashi, Shu-ichi Hashimoto,
Rosa Rapuano Lembo, Lorenzo Manna, Koji Nakamura and Claudia De Lorenzo

Journal ： International Journal of Molecular Sciences
View Source

About TribodyTM

The Tribody technology enables the generation of multi-specific antibody products. This unique technology overcomes the key shortcomings of conventional mono- as well as of currently developed bi-specific antibody formats. Tribody enables creation of unique antibody by building multi-binding sites that bind to different antigen or epitope, which differentiate from conventional antibody. It is expected to generate antibodies against targets that could not be made into pharmaceuticals, and to generate antibodies that can be released from the combination drugs therapy.